Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back
Scientific Session

Systemic lupus erythematosus (SLE)
General Topic: Clinical Science

12S111: Lupus Prevention and Disease-Modifying Anti-Lupus Drugs (DMALDs), Are We There Yet?

Sunday, November 12, 2023
9:00 AM – 10:00 AM PT
Location: Room 11A-B
CE: 1

In Person On Demand

    Speaker(s)

  • AA

    Anca Askanase, MD, MPH

    Director
    Columbia University Medical Center
    New York, NY, United States

    Disclosure(s): Amgen: Data Safety Monitoring Board (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing); Bristol-Myers Squibb(BMS): Clinical Trial Steering Committee (Ongoing); Genentech: Investigator in clinical trail (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Idorsia: Lead PI for clinical trial (Ongoing); Sanofi: Lead PI clinical trial (Ongoing)

  • Maria Dall'Era, MD (she/her/hers)

    Director
    UCSF
    Corte Madera, CA, United States

    Disclosure(s): Annexon Biosciences: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Aurinia: Consultant (Ongoing); Biogen: Consultant (Ongoing); GlaxoSmithKlein: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing)

  • DK

    David Karp, MD, PhD

    UT Southwestern Medical Center
    Dallas, TX, United States

    Disclosure(s): Ampel Biosciences: Consultant (Ongoing); Biogen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing); Celgene: Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); Provention Bio: Advisor or Review Panel Member (Ongoing); Rilite: Grant/Research Support (Terminated, March 3, 2023); UCB: Grant/Research Support (Ongoing)

This session will describe the novel concept of disease modification in lupus. We will consider a similar framework used to classify medications as disease-modifying antirheumatic drugs for rheumatoid arthritis and apply this framework to medications used to treat and prevent systemic lupus erythematous. We will also discuss the concept of prevention of lupus and provide understanding of ongoing studies in the prevention of lupus.

Learning Objectives:

  • Understand the evidence for prevention of systemic lupus erythematous (SLE).
  • Discuss the proposed definition of disease modification in SLE.
  • Discuss how this definition might apply to commonly used SLE medications, disease-modifying anti-lupus drugs (DMALDs).

Presentations:

  • 9:00 AM – 9:15 AM PT
    Can Lupus Be Prevented?

    Speaker: David Karp, MD, PhD – UT Southwestern Medical Center

  • 9:15 AM – 9:30 AM PT
    Disease Modification in SLE-Definition

    Speaker: Maria Dall'Era, MD (she/her/hers) – UCSF

  • 9:30 AM – 9:45 AM PT
    Can Current Lupus Treatments Be Classified as DMALDs?

    Speaker: Anca Askanase, MD, MPH – Columbia University Medical Center

  • 9:45 AM – 10:00 AM PT
    Q&A